Biomedicines (Aug 2021)

How Are Adenosine and Adenosine A<sub>2A</sub> Receptors Involved in the Pathophysiology of Amyotrophic Lateral Sclerosis?

  • Akihisa Mori,
  • Brittany Cross,
  • Shinichi Uchida,
  • Jill Kerrick Walker,
  • Robert Ristuccia

DOI
https://doi.org/10.3390/biomedicines9081027
Journal volume & issue
Vol. 9, no. 8
p. 1027

Abstract

Read online

Adenosine is extensively distributed in the central and peripheral nervous systems, where it plays a key role as a neuromodulator. It has long been implicated in the pathogenesis of progressive neurogenerative disorders such as Parkinson’s disease, and there is now growing interest in its role in amyotrophic lateral sclerosis (ALS). The motor neurons affected in ALS are responsive to adenosine receptor function, and there is accumulating evidence for beneficial effects of adenosine A2A receptor antagonism. In this article, we focus on recent evidence from ALS clinical pathology and animal models that support dynamism of the adenosinergic system (including changes in adenosine levels and receptor changes) in ALS. We review the possible mechanisms of chronic neurodegeneration via the adenosinergic system, potential biomarkers and the acute symptomatic pharmacology, including respiratory motor neuron control, of A2A receptor antagonism to explore the potential of the A2A receptor as target for ALS therapy.

Keywords